Compare HDB & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HDB | NVO |
|---|---|---|
| Founded | 1994 | 1923 |
| Country | India | Denmark |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.3B | 212.7B |
| IPO Year | N/A | N/A |
| Metric | HDB | NVO |
|---|---|---|
| Price | $35.94 | $50.36 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $54.25 |
| AVG Volume (30 Days) | 3.5M | ★ 18.5M |
| Earning Date | 01-21-2026 | 02-04-2026 |
| Dividend Yield | 1.07% | ★ 2.45% |
| EPS Growth | N/A | ★ 10.06 |
| EPS | 0.53 | ★ 3.67 |
| Revenue | $30,210,861,338.00 | ★ $49,580,393,058.00 |
| Revenue This Year | N/A | $7.77 |
| Revenue Next Year | $9.75 | $1.86 |
| P/E Ratio | $20.77 | ★ $13.69 |
| Revenue Growth | N/A | ★ 16.64 |
| 52 Week Low | $28.89 | $43.08 |
| 52 Week High | $39.81 | $111.17 |
| Indicator | HDB | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 46.31 | 55.75 |
| Support Level | $34.83 | $46.08 |
| Resistance Level | $36.02 | $50.75 |
| Average True Range (ATR) | 0.58 | 1.07 |
| MACD | 0.09 | 0.54 |
| Stochastic Oscillator | 52.29 | 92.83 |
HDFC Bank Ltd is an Indian bank. It operates in the following segments: Treasury, Retail banking, Wholesale banking, and Other banking business. The maximum revenue for the company is generated from its Retail banking segment, which serves retail customers through its branch network and other channels. This segment raises customer deposits and provides loans and other services to customers using different product groups. Its other operations include providing wholesale banking services to corporates, government entities, and other enterprises, generating income from its treasury operations, and performing para-banking activities such as offering credit cards, debit cards, etc. Geographically, the company generates a majority of its revenue from its operations in India.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.